抗體寡核苷酸結合物（AOC）市場：2031 年預測

全球抗體寡核苷酸結合物 (AOC) 市場規模預計將從 2026 年的 312 萬美元成長到 2031 年的 2.9141 億美元，預測期內 (2026-2031) 的年複合成長率（CAGR）為 147.78%。

預計到 2031 年，美國和加拿大抗體寡核苷酸結合物 (AOC) 市場規模將達到 1.6503 億美元，高於 2026 年的 204 萬美元，預測期內（2026-2031 年）的複合年成長率為 140.81%。

歐洲抗體寡核苷酸結合物 (AOC) 市場規模預計將從 2026 年的 108 萬美元成長到 2031 年的 9,695 萬美元，預測期內（2026-2031 年）的複合年成長率為 145.73%。

抗體寡核苷酸結合物 (AOC) 市場的主要企業包括 Avidity Biosciences、Dyne Therapeutics、Tallac Therapeutics、Gennao Bio、ChainGen Bio 和 Denali Therapeutics。隨著AOC領域技術創新的不斷推進，競爭也逐漸加劇。特別是在癌症和神經退化性疾病領域，各大公司不斷推出候選藥物，市場競爭預計將愈加激烈。

報告內容

抗體寡核苷酸結合物（AOC）全球市場規模概況。它分析全球市場趨勢，並提供 2020 年至 2024 年的歷史市場收益數據、2024 年的估計和預測以及截至 2031 年的複合年成長率預測。

該報告還探討了主要的抗體寡核苷酸結合物 (AOC) 生產商，並提供了主要地區和國家收益資訊。關注抗體寡核苷酸結合物 (AOC) 未來市場潛力的關鍵亮點和主要地區/國家，以預測該市場分為不同的細分市場和子區隔。我們為美國、墨西哥、巴西、中國、日本、韓國、東南亞、印度、德國、英國、義大利、中東和非洲等國家提供逐國數據和市場價值分析。

本報告重點關注抗體寡核苷酸結合物 (AOC) 的收益、市場佔有率和主要企業的行業排名，數據從 2020 年到 2024 年。確定全球抗體寡核苷酸結合物 (AOC) 市場的主要相關人員，並根據最近的發展和各細分市場的收益分析競爭格局和市場定位。該報告將幫助相關人員了解競爭格局並獲得更深入的見解，以更好地定位他們的業務和市場策略。

本報告分析了 2020 年至 2031 年按類型和應用分類的細分數據、收益和成長率。評估抗體寡核苷酸結合物 (AOC)收益、預測成長趨勢、生產技術、應用和最終用戶產業，包括市場規模和預測。

目錄

第1章 報告概述

• 研究範圍
• 按類型進行市場分析
• 按應用分類的市場
• 假設和限制
• 研究目標
• 目標年份

第2章 全球經濟成長趨勢

• 全球抗體寡核苷酸偶聯物（AOC）市場展望（2020-2031）
• 全球抗體寡核苷酸結合物（AOC）市場成長趨勢（按地區）
• 抗體寡核苷酸偶聯物（AOC）市場動態

第3章 競爭格局及主要參與企業

第4章 抗體-寡核苷酸偶聯物（AOC）細分資料（按類型）

• 全球抗體寡核苷酸結合物（AOC）市場規模（按類型）（2020-2025）
• 全球抗體寡核苷酸結合物（AOC）市場規模預測（2026-2031）

第5章 抗體-寡核苷酸偶聯物（AOC）的細分資料（依應用）

• 全球抗體寡核苷酸結合物（AOC）市場規模及應用（2020-2025）
• 全球抗體寡核苷酸結合物（AOC）市場規模預測（按應用）（2026-2031）

第6章 北美

第7章 歐洲

第8章 中國

第9章 亞洲（不包括中國）

第10章：中東、非洲和拉丁美洲

第11章主要企業簡介

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Denali Therapeutics
• Gennao Bio
• ChainGen Bio

第12章產業鍊及銷售管道分析

• 抗體寡核苷酸偶聯物（AOC）產業鏈分析
• 抗體寡核苷酸偶聯物（AOC）的關鍵原料
• 抗體寡核苷酸偶聯物（AOC）的銷售和行銷
• 抗體寡核苷酸偶聯物 (AOC) 客戶

第 13 章 分析師觀點/結論

第14章 附錄

The global Antibody-oligonucleotide Conjugates (AOCs) market is projected to grow from US$ 3.12 million in 2026 to US$ 291.41 million by 2031, at a Compound Annual Growth Rate (CAGR) of 147.78% during the forecast period (2026-2031).

The US & Canada market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 2.04 million in 2026 to reach $ 165.03 million by 2031, at a CAGR of 140.81% during the forecast period of 2026 through 2031.

The Europe market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 1.08 million in 2026 to reach $ 96.95 million by 2031, at a CAGR of 145.73% during the forecast period of 2026 through 2031.

The global key companies of Antibody-oligonucleotide Conjugates (AOCs) include Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc. As innovations continue to emerge in the field of AOCs, competition is also gradually intensifying. Major companies continue to launch new drug candidates, especially in the fields of cancer and neurodegenerative diseases, and the competition for market share will become more intense.

Report Includes

This report presents an overview of global market for Antibody-oligonucleotide Conjugates (AOCs) market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2024, and projections of CAGR through 2031.

This report researches the key producers of Antibody-oligonucleotide Conjugates (AOCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-oligonucleotide Conjugates (AOCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-oligonucleotide Conjugates (AOCs) revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Antibody-oligonucleotide Conjugates (AOCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Antibody-oligonucleotide Conjugates (AOCs) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc.

Market Segmentation

By Company

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Denali Therapeutics
• Gennao Bio
• ChainGen Bio

Segment by Type

• Site-specific Conjugation

Random Conjugation

• Segment by Application
• Rare and Genetic Diseases
• Cancer Treatment
• Central Nervous System Disorders

By Region

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• Latin America
• Mexico
• Brazil
• Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-oligonucleotide Conjugates (AOCs) revenue, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials and customers.

Chapter 13: Analyst's Viewpoints/Conclusions

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2026 VS 2031
  • 1.2.2 Site-specific Conjugation
  • 1.2.3 Random Conjugation
• 1.3 Market by Application
  • 1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031
  • 1.3.2 Rare and Genetic Diseases
  • 1.3.3 Cancer Treatment
  • 1.3.4 Central Nervous System Disorders
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
• 2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
  • 2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2031
  • 2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
  • 2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
• 2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
  • 2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
  • 2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
  • 2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
  • 2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Antibody-oligonucleotide Conjugates (AOCs) by Players
  • 3.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025)
  • 3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
• 3.2 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
• 3.3 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
• 3.4 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type

• 4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
• 4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)

5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application

• 5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
• 5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)

6 North America

• 6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 6.2.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 6.2.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 6.2.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• 6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 6.3.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 6.3.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 6.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• 6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 6.4.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 6.4.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 6.4.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
  • 6.4.4 United States
  • 6.4.5 Canada

7 Europe

• 7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 7.2.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 7.2.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 7.2.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• 7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 7.3.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 7.3.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 7.3.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• 7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 7.4.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 7.4.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 7.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
  • 7.4.4 Germany
  • 7.4.5 France
  • 7.4.6 U.K.
  • 7.4.7 Italy
  • 7.4.8 Russia

8 China

• 8.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 8.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 8.2.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 8.2.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 8.2.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)
• 8.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 8.3.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 8.3.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 8.3.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)

9 Asia (excluding China)

• 9.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 9.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 9.2.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 9.2.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 9.2.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• 9.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 9.3.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 9.3.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 9.3.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• 9.4 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region
  • 9.4.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2027 VS 2031
  • 9.4.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
  • 9.4.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
  • 9.4.4 Japan
  • 9.4.5 South Korea
  • 9.4.6 Southeast Asia
  • 9.4.7 India
  • 9.4.8 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 10.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 10.2.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 10.2.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• 10.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 10.3.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 10.3.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)
• 10.4 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 10.4.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 10.4.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
  • 10.4.4 Mexico
  • 10.4.5 Brazil
  • 10.4.6 Middle East & Africa

11 Key Players Profiles

• 11.1 Avidity Biosciences
  • 11.1.1 Avidity Biosciences Company Details
  • 11.1.2 Avidity Biosciences Business Overview
  • 11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031
  • 11.1.5 Avidity Biosciences Recent Development
• 11.2 Dyne Therapeutics
  • 11.2.1 Dyne Therapeutics Company Details
  • 11.2.2 Dyne Therapeutics Business Overview
  • 11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.2.5 Dyne Therapeutics Recent Development
• 11.3 Tallac Therapeutics
  • 11.3.1 Tallac Therapeutics Company Details
  • 11.3.2 Tallac Therapeutics Business Overview
  • 11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.3.5 Tallac Therapeutics Recent Development
• 11.4 Denali Therapeutics
  • 11.4.1 Denali Therapeutics Company Details
  • 11.4.2 Denali Therapeutics Business Overview
  • 11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.4.5 Denali Therapeutics Recent Development
• 11.5 Gennao Bio
  • 11.5.1 Gennao Bio Company Details
  • 11.5.2 Gennao Bio Business Overview
  • 11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
• 11.6 ChainGen Bio
  • 11.6.1 ChainGen Bio Company Details
  • 11.6.2 ChainGen Bio Business Overview
  • 11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031

12 Industry Chain and Sales Channels Analysis

• 12.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Chain Analysis
• 12.2 Antibody-oligonucleotide Conjugates (AOCs) Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Antibody-oligonucleotide Conjugates (AOCs) Sales and Marketing
• 12.4 Antibody-oligonucleotide Conjugates (AOCs) Customers

13 Analyst's Viewpoints/Conclusions

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
  • 14.1.2 Data Source
• 14.2 Author Details
• 14.3 Disclaimer 97

List of Tables

• Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (US$ Million): 2026 VS 2031
• Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (US$ Million): 2026 VS 2031
• Table 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2026 VS 2031
• Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
• Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2025)
• Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)
• Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2031)
• Table 8. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
• Table 9. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
• Table 10. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
• Table 11. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
• Table 12. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025) & (US$ Million)
• Table 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2020-2025)
• Table 14. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Headquarters and Area Served
• Table 15. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
• Table 16. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
• Table 17. Mergers & Acquisitions, Expansion Plans
• Table 18. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 19. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2020-205)
• Table 20. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)
• Table 21. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2026-2031)
• Table 22. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2020-205)
• Table 24. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)
• Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2026-2031)
• Table 26. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 27. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 28. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 29. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 30. North America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031
• Table 31. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 32. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 33. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 35. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 36. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 37. Europe Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031
• Table 38. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 39. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 40. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 41. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 42. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 43. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 44. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 45. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 46. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 47. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 48. Asia Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Region (US$ Million): 2027 VS 2031
• Table 49. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
• Table 50. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031) & (US$ Million)
• Table 51. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 52. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 53. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 54. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 55. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2027 VS 2031
• Table 56. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 57. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 58. Avidity Biosciences Company Details
• Table 59. Avidity Biosciences Business Overview
• Table 60. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 61. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031 & (US$ Million)
• Table 62. Avidity Biosciences Recent Development
• Table 63. Dyne Therapeutics Company Details
• Table 64. Dyne Therapeutics Business Overview
• Table 65. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 66. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 67. Dyne Therapeutics Recent Development
• Table 68. Tallac Therapeutics Company Details
• Table 69. Tallac Therapeutics Business Overview
• Table 70. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 71. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 72. Tallac Therapeutics Recent Development
• Table 73. Denali Therapeutics Company Details
• Table 74. Denali Therapeutics Business Overview
• Table 75. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 76. Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 77. Denali Therapeutics Recent Development
• Table 78. Gennao Bio Company Details
• Table 79. Gennao Bio Business Overview
• Table 80. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 81. Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 82. ChainGen Bio Company Details
• Table 83. ChainGen Bio Business Overview
• Table 84. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 85. ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 86. Raw Materials Key Suppliers Lists
• Table 87. Antibody-oligonucleotide Conjugates (AOCs) Customers List
• Table 88. Research Programs/Design for This Report
• Table 89. Key Data Information from Secondary Sources
• Table 90. Key Data Information from Primary Sources

List of Figures

• Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
• Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type, (2020-2031) & (US$ Million)
• Figure 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type: 2026 VS 2031
• Figure 4. Site-specific Conjugation Picture
• Figure 5. Random Conjugation Picture
• Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Application, 2026-2031 (US$ Million)
• Figure 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031
• Figure 8. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered
• Figure 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size (US$ Million), Year-over-Year: 2020-2031
• Figure 10. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (US$ Million), 2026 VS 2031
• Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region: 2026 VS 2031
• Figure 12. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 13. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• Figure 14. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• Figure 15. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
• Figure 16. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 17. Canada Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 18. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 19. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• Figure 20. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• Figure 21. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
• Figure 22. Germany Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 23. France Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 24. U.K. Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 25. Italy Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 26. Russia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 27. China Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 28. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)
• Figure 29. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• Figure 30. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 31. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• Figure 32. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• Figure 33. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2031)
• Figure 34. Japan Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 35. South Korea Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 36. Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 37. India Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 38. Australia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 39. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 40. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• Figure 41. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)
• Figure 42. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2027-2031)
• Figure 43. Mexico Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 44. Brazil Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 45. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 46. Antibody-oligonucleotide Conjugates (AOCs) Value Chain
• Figure 47. Bottom-up and Top-down Approaches for This Report
• Figure 48. Data Triangulation
• Figure 49. Key Executives Interviewed